2020
DOI: 10.1016/j.lfs.2020.117960
|View full text |Cite
|
Sign up to set email alerts
|

Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation–predominant irritable bowel syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 21 publications
0
10
0
Order By: Relevance
“…There are few studies evaluating the effects of tadalafil on healthy athletes [ 27 , 53 , 54 , 55 ]. Many studies have been conducted on subjects with pathologies or who are in conditions of extreme physiological stress [ 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ]. Recently, using a similar group of subjects, we have demonstrated that a single dose of tadalafil did not substantially influence performance indicators, during a maximal standardized exercise test in a healthy athlete [ 27 ].…”
Section: Discussionmentioning
confidence: 99%
“…There are few studies evaluating the effects of tadalafil on healthy athletes [ 27 , 53 , 54 , 55 ]. Many studies have been conducted on subjects with pathologies or who are in conditions of extreme physiological stress [ 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ]. Recently, using a similar group of subjects, we have demonstrated that a single dose of tadalafil did not substantially influence performance indicators, during a maximal standardized exercise test in a healthy athlete [ 27 ].…”
Section: Discussionmentioning
confidence: 99%
“…Three rats of each group were separated for measurement of the intestinal transit and cGMP level. According to the literature the intestinal transit was measured by administration of powdered charcoal via gastric gavage ( Sagar et al, 2005 , Sedky and Magdy, 2020 , Sharman et al, 2017 ). After one hour; they were sacrificed and the small and large intestines were isolated.…”
Section: Methodsmentioning
confidence: 99%
“…In 2012, linaclotide; GC-C agonist, gained FDA approval for the treatment of constipation-predominant IBS ( Eswaran et al, 2014 , Love et al, 2014 ). However, the use of GC-C agonists in pediatrics was limited as they may cause severe diarrhea ( Sedky and Magdy, 2020 ). cGMP-elevating agents such as phosphodiesterase 5 (PDE-5) inhibitors are recently reported as a promising medication in pediatrics ( Eswaran et al 2014 ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Applic. 33, No.1 (2020) bowel syndrome besides the related behavior deviations (Sedky & Magdy, 2020;Singh et al, 2020;Zuccarello et al, 2020).…”
Section: Introductionmentioning
confidence: 99%